Search - tctmd.com

Displaying 1 - 20 of 68

Sort: Relevancy | Date

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

News Conference News CX Symposium 2025

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

April 23, 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

News Conference News CRT 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

March 10, 2025

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

November 01, 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

October 29, 2024

Protecting Coronary Access After TAVI: Valve Choice Clues From CAVEAT

News Conference News TCT 2024

Protecting Coronary Access After TAVI: Valve Choice Clues From CAVEAT

Michael O'Riordan

October 27, 2024

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

News Conference News TCT 2023

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

Michael O'Riordan

November 01, 2023

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

News Conference News TCT 2023

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

October 27, 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

News Conference News TCT 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

October 25, 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

FIRE: Complete Revascularization Best Even for Elderly Patients With MI

News Conference News ESC 2023

FIRE: Complete Revascularization Best Even for Elderly Patients With MI

Michael O'Riordan

August 26, 2023

Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis

News Conference News SCAI 2023

Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis

May 22, 2023

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

News Conference News ACC 2023

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

Yael L. Maxwell

March 09, 2023

Late Catch-up Sours SUGAR for Polymer-Free Stent in Diabetic Patients

News Conference News TCT 2022

Late Catch-up Sours SUGAR for Polymer-Free Stent in Diabetic Patients

Yael L. Maxwell

September 27, 2022

Imaging in PCI for Patients at High Bleeding Risk: Data Point to Possibilities

News Conference News EuroPCR 2022

Imaging in PCI for Patients at High Bleeding Risk: Data Point to Possibilities

May 25, 2022

Managing AF Patients Undergoing PCI—Some Lingering Questions

News Conference News ACC 2022

Managing AF Patients Undergoing PCI—Some Lingering Questions

Michael O'Riordan

April 12, 2022

News Conference News TCT 2021

DCBs in Coronaries? Some Good News, but More Work Needed

November 06, 2021

Left Main Guideline Review Looms as EACTS Surgeons Urge CABG First

News Conference News EACTS 2021

Left Main Guideline Review Looms as EACTS Surgeons Urge CABG First

Michael O'Riordan

October 19, 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

October 12, 2021

In ACS, Clopidogrel Monotherapy After 1-Month DAPT Falls Short: STOPDAPT-2 ACS

News Conference News

In ACS, Clopidogrel Monotherapy After 1-Month DAPT Falls Short: STOPDAPT-2 ACS

August 30, 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

News Conference News ESC 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

August 28, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.